Alaunos Therapeutics (TCRT) Current Assets (2009 - 2026)

Alaunos Therapeutics has reported Current Assets for 18 years, with the latest figure at $970000.0 in Q1 2026.

• For the quarter ending Q1 2026, Current Assets fell 9.09% year-over-year to $970000.0; the trailing twelve-month figure through Mar 2026 stood at $970000.0 (down 9.09% YoY), and the FY2025 full-year result was $2.0 million, down 27.84% from the prior year.
• Current Assets for Q1 2026 stood at $970000.0, down from $2.0 million in the prior quarter.
• The five-year high for Current Assets was $69.8 million in Q1 2022, with the low at $970000.0 in Q1 2026.
• Historically, Current Assets has averaged $20.4 million across 5 years, with a median of $6.0 million in 2024.
• Annual changes were most pronounced in 2023 — Current Assets sank 84.64% — and 2026, when it declined 9.09%.
• Alaunos Therapeutics' Current Assets stood at $53.8 million in 2022, then slumped by 84.64% to $8.3 million in 2023, then slumped by 66.65% to $2.8 million in 2024, then slipped by 27.84% to $2.0 million in 2025, then sank by 51.21% to $970000.0 in 2026.
• The last three Current Assets figures came in at $970000.0 (Q1 2026), $2.0 million (Q4 2025), and $2.7 million (Q3 2025), per Business Quant data.